Market Update (NYSE:MRK): Merck to Present New Data for KEYTRUDA® (pembrolizumab) at the American Association for Cancer Research 2016 Annual Meeting

[Business Wire] – Merck , known as MSD outside the United States and Canada, today announced that new research investigating the use of KEYTRUDA® , the company’s anti-PD-1 therapy, in multiple tumor types, both as a single agent and in combination with other therapies, will be presented at this year’s American Association for Cancer Research Annual Meeting in New Orleans, April 16 – 20. Read more on this. Merck & Co. Inc. (MRK) , currently valued at $153.58B, opened this morning at $54.35. During the trading session, MRK traded between $54.26 to $55.39 and has traded between $45.69 and $61.70 over the past year. MRK shares are currently priced at 14.70x this year’s forecasted earnings, which makes them relatively expensive compared to the industry’s -2.39x earnings multiple. And for those looking to make a return holding the stock, the company pays shareholders $1.84 per share annually in dividends, yielding 3.43%. In a review of the consensus earnings estimate this quarter, 17 sell-side analysts are looking at $0.85 per share, which would be $0.00 worse than the year-ago quarter and a $0.02 sequential increase. In looking at the bigger picture, the full-year EPS estimate of $3.70 would be a $0.11 improvement when compared to the previous year’s annual results. The quarterly earnings estimate is predicated on a consensus revenue forecast of $9.45 Billion. If reported, that would be a 0.32% increase over the year-ago quarter. More recently, BofA/Merrill downgraded MRK from Buy to Neutral (Jan 27, 2016). Previously, Berenberg Initiated MRK at to Hold. With the above information in mind, readers should note that the average price target is $60.16, which is 10.69% above where the stock opened this morning. See more in (NYSE:MRK) Similar Articles: Company Update (NYSE:MRK): FDA Approves Expanded Indication for Merck’s KEYTRUDA® (pembrolizumab) for the Treatment of Patients with Advanced Melanoma Company Update: Merck & Co Inc (NYSE:MRK) – Merck’s Pembrolizumab Shows Superior Overall Survival Compared to Chemotherapy in Patients with Previously Treated Advanced Non-Small Cell Lung Cancer Whose Tumors Express PD-L1 Market Update (NYSE:MRK): Dynavax Initiates Immuno-Oncology Clinical Trial Evaluating SD-101 in Combination With Merck’s Anti-PD-1 Therapy, KEYTRUDA(R) (pembrolizumab)
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.